Intravitreal injection of anti vascular endothelial growth factor agent, Lucentis (ranibizumab), for the treatment of retinopathy of prematurity

Intravitreal injection of anti vascular endothelial growth factor agent, Lucentis (ranibizumab), for the treatment of retinopathy of prematurity - IVR for ROP

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013975

Enrollment

Registered

2014-05-19

Start date

2014-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinopathy of prematurity

Interventions

intravitreal injection of ranibizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: severe cases of retinopathy of prematurity that are not controled after laser photocoagulation

Exclusion criteria

Exclusion criteria: inflammation around the eye

Design outcomes

Primary

Measure	Time frame
prevention of retinal detachment serous VEGF concentration	—

Secondary

Measure	Time frame
visual acuity	—

Countries

Japan

Contacts

Public ContactNorie Nonobe

Nagoya university hospital ophthalmology

nonobe@med.nagoya-u.ac.jp052-744-2275

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026